The oral bioavailability of the insulin-loaded DLPC MSNs was able to decrease 55% of the original blood glucose level in STZ-induced type 1 diabetic rats, which was significantly greater than that of free oral insulin and that of unmodified MSNs [80]. The gene discussed is INS; the disease is type 1 diabetes mellitus.